MORRISVILLE and RESEARCH TRIANGLE PARK, N.C. – In a collaborative effort designed to increase the speed and efficiency of late-phase clinical research, etrials Worldwide, Inc. and Quintiles Transnational Corp. recently announced that they have entered into an arrangement to license etrials’ eClinical Suite of software and to collaborate to develop technology specifically for use in peri-approval studies.
etrials is a provider of eClinical software for the efficient collection, cleaning, integration and review of data in the clinical trial process. Quintiles Transnational is a leading provider of services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries.
As part of the arrangement, etrials will augment its existing eClinical Suite by developing a new Phase IV product offering to take advantage of the valuable data collected in late-stage and post-approval trials. The new products will combine Quintiles’ expertise in the post-approval market, including certain technology transferred to etrials, and etrials’ best-in-class technology.”This partnership will further diversify the technologies Quintiles offers our clients with etrials’ fully integrated electronic data capture and interactive voice response technologies,” said Dr. Hugo Stephenson, president of Strategic Research Services for Quintiles. “Building on our expertise and experience in data management, our strategic investment in the development of a clinical trial management system and Phase IV specific tools will be a great asset to our clients.”
The three-year licensing agreement provides Quintiles’ clients with etrials’ fully integrated suite of eClinical tools for use in late-phase studies, including electronic data capture; interactive voice response; and reporting/analytic tools. The contract also provides etrials with backlog and ongoing work relating to ten late-phase clinical trials already in progress that will be supported by etrials.
“With the pharmaceutical and biotechnology industries experiencing a shift in focus to dynamic trials and safety, partnering with Quintiles is an exciting opportunity to provide a wider base of clinical researchers with the integral data they need to make the best decisions,” said John Cline, CEO of etrials. “Quintiles and etrials share the common vision of making clinical research easier for our valued clients. Together, we are eager to providethose benefits to our global partners.”
